TopleyN., AlobaidiH.M., DaviesM., ColesG.A., WilliamsJ.D., LloydD.The effect of dialysate on peritoneal phagocyte oxidative metabolism.Kidney Int1988; 34: 404–11.
2.
GoldsteinC.S., BomalaskiJ.S., ZurierR.B., NeilsonE.G., DouglasS.D.Analysis of peritoneal macrophages in continuous ambulatory peritoneal dialysis patients.Kidney Int1984; 26: 733–40.
3.
JörresA., JörresD., TopleyN., GahlG.M., MahioutA.Leukotriene release from peripheral and peritoneal leukocytes following exposure to peritoneal dialysis solutions.Nephrol Dial Transplant1991; 6: 495–501.
4.
AlobaidiH.M., ColesG.A., DaviesM., LloydD.Host defence in continuous ambulatory peritoneal dialysis: the effect of the dialysate on phagocyte functionNephrol Dial Transplant1986; 1: 16–21.
5.
GallimoreB., GagnonR.F., StevensonM.M.Cytotoxicity of commercial peritoneal dialysis solutions towards peritoneal cells of chronically uremic mice.Nephron1986; 43: 283–9.
6.
JörresA, JörresD., GahlG.M.Leukotriene B4 and tumor necrosis factor release from leukocytes: effect of peritoneal dialysate.Nephron1991; 58: 276–82.
7.
DuweA.K., VasS.I., WeatherheadJ.W.Effects of the composition of peritoneal dialysis fluid on chemiluminescence, phagocytosis, and bactericidal activity in vitro.Infect Immun1981; 33: 130–5.
8.
GuptaD.K., IngB.L., ManahanF.J.Superoxide generation by neutrophils after exposure to a conventional peritoneal dialysis solution for different time periods.Int J Artif Organs1990; 13: 228–30.
9.
IngB.L., GuptaD.K., NawabZ.M., ZhouF.Q., RahmanM.A., DaugirdasJ.T.Suppression of neutrophil superoxide production by conventional peritoneal dialysis solution.Int J Artif Organs1988; 11: 351–4.
10.
LiberekT., TopleyN., JörresA.Peritoneal dialysis fluid inhibition of polymorphonuclear leukocyte respiratory burst activation is related to the lowering of intracellular pH.Nephron1993; 65: 260–5.
11.
Van BronswijkH., VerbrughH.A., HeeziusH.C., Van der MeulenJ., OeP.L., VerhoefJ.Dialysis fluids and local host resistance in patients on continuous ambulatory peritoneal dialysis.Eur J Clin Microbiol Infect Dis1988; 7: 368–73.
12.
LiberekT., TopleyN., JörresA., ColesG.A., GahlG.M., WilliamsJ.D.Peritoneal dialysis fluid inhibition of phagocyte function: effects of osmolality and glucose concentration.J Am Soc Nephrol1993; 3: 1508–15.
13.
De FijterC.W., VerbrughH.A., PetersE.D.Another reason to restrict the use of a hypertonic, glucose-based peritoneal dialysis fluid: its impact on peritoneal macrophage function in vivo. In: KhannaR., NolphK.D., ProwantB.F., TwardowskiZ.J., OreopoulosD.G., eds. Advances in peritoneal dialysis.Toronto: Peritoneal Dialysis Bulletin, 1991; 7: 150–3.
14.
De FijterC.W., VerbrughH.A., PetersE.D.In vivo exposure to the currently available peritoneal dialysis fluids decreases the function of peritoneal macrophages in CAPD.Clin Nephrol1993; 39: 75–80.
15.
TopleyN., MackenzieR., JörresA., ColesG.A., DaviesM., WilliamsJ.D.Cytokine networks in continuous ambulatory peritoneal dialysis: interactions of resident cells during inflammation in the peritoneal cavity.Perit Dial Int1993; 13(Suppl 2): S282–5.
16.
JörresA., JörresD., GahlG.M., SchulzE., MahioutA.Peritoneal dialysate inhibits leukotriene release from peripheral and peritoneal polymorphonuclear leukocytes (Abstract).Artif Organs1991; 15: 331.
17.
SteinhauerH.B., BruggerU., AtmanspacherR., Lubrich BirknerI., SchollmeyerP.Effect of CAPD dialysate on the release of eicosanoids and cytokines from human peritoneal macrophages. In: KhannaR., NolphK.D., ProwantB.F., TwardowskiZ.J., OreopoulosD.G., eds. Advances in peritoneal dialysis.Toronto: Peritoneal Dialysis Bulletin, 1992; 8: 47–52.
18.
JörresA, GoldmanM., AbramowiczD.Interleukin 6 and tumor necrosis factor release from mononuclear leukocytes: inhibition by peritoneal dialysate. In: OtaK., WinchesterJ.F., MaherJ.F., HirszelP., eds. Current concepts in peritoneal dialysis.Amsterdam: Elsevier Science, 1992: 292.
19.
JörresA., TopleyN., WitowskiJ., LiberekT., GahlG.M.Impact of peritoneal dialysis solutions on peritoneal immune defense.Perit Dial Int1993; 13(Suppl 2) S291–4.
20.
JörresA., TopleyN., SteenwegL., MullerC., KöttgenE., GahlG.M.Inhibition of cytokine synthesis by peritoneal dialysate persists throughout the CAPD cycle.Am J Nephrol1992; 12: 80–5.
21.
DouvdevaniA., RapoportJ., KonfortiA., ZlotnikM., ChaimovitzC.The effect of peritoneal dialysis fluid on the release of IL-Iβ and TNFα by macrophages/monocytes.Perit Dial Int1993; 13: 112–17.
JörresA., TopleyN., ScholzP., LudatK., MullerC., GahlG.M.CAPD and cytokines: peritoneal dialysate inhibits the production of IL-8, IL-6 and TNF alpha (Abstract).J Am Soc Nephrol1992; 3: 418.
24.
De FijterC.W., VerbrughH.A., OeL.P.Biocompatibility of a glucose-polymer-containing peritoneal dialysis fluid.Am J Kidney Dis1993; 21: 411–18.
25.
LiberekT., TopleyN., MistryC.D.Cell function and viability in glucose polymer peritoneal dialysis fluids.Perit Dial Int1993; 13: 104–11.
26.
JörresA., GahlG.M., TopleyN.In vitro-biocompatibility of alternative CAPD fluids; comparison of bicarbonate-buffered and glucose polymer-based solutions.Nephrol Dial Transplant1994; 9: 785–90.
27.
SchambyeH.T., PedersenF.B., ChristensenH.K., BerthelsenH., WangP.The cytotoxicity of continuous ambulatory peritoneal dialysis solutions with different bicarbonate/lactate ratios.Perit Dial Int1993; 13(Suppl 2): S116–18.
28.
SchambyeH.T., FlesnerP., PedersenR.B.Bicarbonate versus lactate-based CAPD fluids: a biocompatibility study in rabbits (see comments).Perit Dial Int1992; 12: 281–6.
